{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-028373","form_type":"8-K","ticker":"IXHL","cik":"0001873875","company_name":"Incannex Healthcare Inc.","filed_at":"2025-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.321380+00:00","generated_at":"2026-05-23T22:48:33.567219+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Incannex completes Phase 2 enrollment in RePOSA trial of IHL-42X for OSA; topline data expected H1 2025","bullets":["Completed enrollment of >120 patients across 11 U.S. sites in Phase 2 dose-finding portion of RePOSA Phase 2/3 study of IHL-42X for OSA.","Topline Phase 2 clinical data expected in first half 2025; results will determine optimal dose for Phase 3.","Phase 3 expansion planned with ~440 patients across four treatment arms over 52 weeks to support future FDA NDA submission.","IHL-42X is an oral fixed-dose combination of dronabinol and acetazolamide targeting physiological pathways of OSA."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-028373","json":"https://secwatch.observer/filing/0001213900-25-028373.json","markdown":"https://secwatch.observer/filing/0001213900-25-028373.md","text":"https://secwatch.observer/filing/0001213900-25-028373.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025028373/0001213900-25-028373-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025028373/ea0237061-8k_incannex.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T22:48:33.567219+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}